Taiwan
· Delayed Price · Currency is TWD Sunny Pharmtech Statistics
Total Valuation
Sunny Pharmtech has a market cap or net worth of TWD 3.60 billion. The enterprise value is 3.77 billion.
| Market Cap | 3.60B |
| Enterprise Value | 3.77B |
Important Dates
The next estimated earnings date is Thursday, November 14, 2024.
| Earnings Date | Nov 14, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Sunny Pharmtech has 148.76 million shares outstanding. The number of shares has increased by 6.71% in one year.
| Shares Outstanding | 148.76M |
| Shares Change (YoY) | +6.71% |
| Shares Change (QoQ) | +1.20% |
| Owned by Insiders (%) | 1.66% |
| Owned by Institutions (%) | 0.00% |
| Float | 131.78M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 7.38 |
| PB Ratio | 3.10 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 69.52, with an EV/FCF ratio of -34.17.
| EV / Earnings | -74.77 |
| EV / Sales | 7.78 |
| EV / EBITDA | 69.52 |
| EV / EBIT | n/a |
| EV / FCF | -34.17 |
Financial Position
The company has a current ratio of 3.24, with a Debt / Equity ratio of 34.05.
| Current Ratio | 3.24 |
| Quick Ratio | 2.32 |
| Debt / Equity | 34.05 |
| Debt / EBITDA | 7.29 |
| Debt / FCF | -3.58 |
| Interest Coverage | -7.14 |
Financial Efficiency
Return on equity (ROE) is -4.83% and return on invested capital (ROIC) is -2.73%.
| Return on Equity (ROE) | -4.83% |
| Return on Assets (ROA) | -2.55% |
| Return on Capital (ROIC) | -2.73% |
| Revenue Per Employee | 3.37M |
| Profits Per Employee | -350,542 |
| Employee Count | 138 |
| Asset Turnover | 0.29 |
| Inventory Turnover | 2.59 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -32.69% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -32.69% |
| 50-Day Moving Average | 24.60 |
| 200-Day Moving Average | 29.04 |
| Relative Strength Index (RSI) | 48.39 |
| Average Volume (20 Days) | 151,143 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Sunny Pharmtech had revenue of TWD 485.01 million and -50.48 million in losses. Loss per share was -0.34.
| Revenue | 485.01M |
| Gross Profit | 281.20M |
| Operating Income | -67.47M |
| Pretax Income | -50.48M |
| Net Income | -50.48M |
| EBITDA | 49.37M |
| EBIT | -67.47M |
| Loss Per Share | -0.34 |
Balance Sheet
The company has 221.23 million in cash and 395.71 million in debt, giving a net cash position of -174.48 million or -1.17 per share.
| Cash & Cash Equivalents | 221.23M |
| Total Debt | 395.71M |
| Net Cash | -174.48M |
| Net Cash Per Share | -1.17 |
| Equity (Book Value) | 1.16B |
| Book Value Per Share | 7.81 |
| Working Capital | 300.55M |
Cash Flow
In the last 12 months, operating cash flow was -11.18 million and capital expenditures -99.27 million, giving a free cash flow of -110.45 million.
| Operating Cash Flow | -11.18M |
| Capital Expenditures | -99.27M |
| Free Cash Flow | -110.45M |
| FCF Per Share | -0.74 |
Margins
Gross margin is 57.98%, with operating and profit margins of -13.91% and -10.41%.
| Gross Margin | 57.98% |
| Operating Margin | -13.91% |
| Pretax Margin | -10.41% |
| Profit Margin | -10.41% |
| EBITDA Margin | 10.18% |
| EBIT Margin | -13.91% |
| FCF Margin | -22.77% |
Dividends & Yields
Sunny Pharmtech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -6.71% |
| Shareholder Yield | -6.71% |
| Earnings Yield | -1.41% |
| FCF Yield | -3.07% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |